Logo of AdAlta (ASX:1AD)Latest AdAlta (ASX:1AD) News

Page 2
Page 2 of 6

AdAlta’s IRO Platform Wins Commercial Validation From US$120 Million Oribiotech Deal

AdAlta says a 10-year, up to US$120 million agreement between manufacturing partner Oribiotech and an undisclosed commercial-stage biopharmaceutical company validates its choice of IRO automation for future cellular immunotherapies. The deal does not create direct revenue for AdAlta, and its lead asset EW-001 will continue with a separate manufacturing process.
Ada Torres
18 Sept 2026

Market Wrap - Week 36 (31 Aug -> 4 Sept) 2026

Small-cap shares produced another uneven week, led by a major fall in Corporate Travel Management and strong gains in energy, gas and takeover stocks.
Investors rewarded rising profits and new deals, but sold several companies despite promising project news.
Logan Eniac
5 Sept 2026

Healthcare Wrap - Week 36 (31 Aug -> 4 Sept) 2026

Healthcare shares delivered a mixed week as commercial wins and trial progress competed with fresh losses and capital needs.
Large moves in Alzheimer’s, fertility, diagnostics and medical devices gave investors clear milestones to track.
Logan Eniac
5 Sept 2026

AdAlta Partner Secures Approval for CAR-T Therapy in China’s Boao Lecheng Zone

AdAlta’s partner SHcell has gained regulatory approval to provide the BZDS1901 CAR-T therapy to advanced mesothelioma patients in China’s Hainan Boao Lecheng special access zone, marking a key milestone in real-world data collection and treatment availability.
Ada Torres
2 Sept 2026

Healthcare Wrap - Week 34 (17 Aug -> 21 Aug) 2026

Healthcare shares delivered a mixed week, with strong gains at AVITA Medical, Australian Clinical Labs and CSL despite very different company results.
Investors also weighed new US approvals, clinical trial progress, funding needs and rising sales across the sector.
Logan Eniac
22 Aug 2026

AdAlta Advances Cellular Immunotherapy Pipeline, Secures First Asset and Raises A$5.3 Million

AdAlta Limited (ASX:1AD) has progressed its ‘East to West’ cellular immunotherapy strategy by securing its first CAR-T asset, advancing Australian manufacturing and US FDA regulatory engagement, while raising A$5.3 million in FY2026 and reporting a net loss of $4.68 million.
Ada Torres
21 Aug 2026

Market Wrap - Week 33 (10 Aug -> 14 Aug) 2026

Small explorers led the ASX week, with Lachlan Star, EcoGraf and Basin Energy recording the biggest gains on new drilling, offtake and exploration news.
Takeovers, capital raisings and strong company results also drew attention, although several large stocks fell despite reporting better earnings.
Logan Eniac
15 Aug 2026

Healthcare Wrap - Week 33 (10 Aug -> 14 Aug) 2026

Healthcare shares delivered mixed results as Percheron surged on a leadership change, while ResMed gained on stronger sales and portfolio changes.
Biotech funding, medical-device expansion and new software contracts shaped the week, but several small-cap gaps quickly lost ground.
Logan Eniac
15 Aug 2026

AdAlta’s EW-001 Shows Durable Survival and Response in Mesothelioma Trial

AdAlta’s lead CAR-T therapy EW-001 continues to demonstrate encouraging survival and response rates in its mesothelioma study, with all patients alive at the latest follow-up and stronger outcomes at higher doses supporting plans for an Australian Phase 1 trial.
Ada Torres
10 Aug 2026

Market Wrap - Week 32 (3 Aug -> 7 Aug) 2026

Small-cap resources stocks led the week, while takeover activity and strong company results added to the gains. Wellnex Life more than doubled, but sharp falls in Trek Metals and Ionic Rare Earths showed that positive news did not always bring buyers.
Logan Eniac
8 Aug 2026

Healthcare Wrap - Week 32 (3 Aug -> 7 Aug) 2026

Wellnex led the healthcare market after agreeing to sell Pain Away for up to A$21.3 million. Neuren and Lumos also rose strongly as sales, royalties and product orders improved.
Logan Eniac
8 Aug 2026

AdAlta’s EW-001 CAR-T Therapy Marks Two-Year Cancer-Free Survival in Mesothelioma Patient

AdAlta’s lead CAR-T therapy EW-001 has achieved a rare clinical milestone with one mesothelioma patient remaining cancer-free two years after treatment, and a second reaching one-year survival, underscoring the therapy’s potential durability in a notoriously difficult cancer.
Ada Torres
5 Aug 2026